Croda Pharma, member of CataloniaBio & HealthTech, has been awarded winner of a prestigious award for its process development for innovative ingredients, including its production of sustainably sourced Squalene to replace shark-derived squalene for the vaccine industry.
The company was awarded the ‘Best Production/Process Development award’ at the 17th Annual ViE Awards 2024. The awards, which celebrate the industry’s most outstanding achievements and contributions to vaccines, recognised Croda Pharma for its process development for sustainably sourced and highly purified Squalene. A process which has unlocked a more sustainable alternative to shark-derived squalene, at the purity level required for vaccines.
This comes closely after Croda announced a key partnership with Amyris, a leading synthetic biotechnology company, to develop and supply sustainably sourced Squalene for vaccines, addressing a key industry challenge in the journey to more sustainable vaccines
Laura Ciccardi, Global Business Development Manager, accepted the award on behalf of Croda and said: “It is a great recognition of all our efforts to make sustainable and innovative adjuvant systems available to the world. I am very proud we have received this award”.
Dennis Christensen, Head of Global Research and Development also added: “We have unlocked a yeast-based, sustainably sourced Squalene of superior quality ≥99% pure, that carries the same benefits as shark-derived squalene. Our Squalene can be used in novel vaccine adjuvant systems applicable in many important vaccines against diseases such as seasonal and pandemic influenza, tuberculosis, shingles, schistosomiasis, HIV, and other vaccine preventable diseases.”
Comments